Details of the Drug Combination

General Information of Drug Combination (ID: DCV5R1K)

• Drug Combination Name: Vismodegib + Raloxifene
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Vismodegib (DM5IXKQ): Small molecular drug
  Raloxifene (DMDKF3M): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HCT116
  Zero Interaction Potency (ZIP) Score: 2.44
  Bliss Independence Score: 8.08
  Loewe Additivity Score: 4.72
  LHighest Single Agent (HSA) Score: 5

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Vismodegib

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Approved	[2]
Primitive neuroectodermal tumour medulloblastoma	2A00.11	Phase 2	[3]

Vismodegib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Smoothened homolog (SMO)	TT8J1S3	SMO_HUMAN	Modulator	[5]

Vismodegib Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[6]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[6]

Vismodegib Interacts with 13 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[7]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[7]
Zinc finger protein GLI1 (GLI1)	OT1BTAJO	GLI1_HUMAN	Decreases Expression	[7]
Zinc finger protein GLI2 (GLI2)	OTIRV97L	GLI2_HUMAN	Decreases Expression	[7]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[7]
Platelet-derived growth factor receptor alpha (PDGFRA)	OTDJXUCN	PGFRA_HUMAN	Decreases Expression	[7]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[7]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Cleavage	[7]
Protein patched homolog 1 (PTCH1)	OTMG07H5	PTC1_HUMAN	Decreases Expression	[7]
Protein smoothened (SMO)	OTXXE208	SMO_HUMAN	Decreases Expression	[7]
Protein patched homolog 2 (PTCH2)	OTOQ0K9V	PTC2_HUMAN	Decreases Expression	[7]
Suppressor of fused homolog (SUFU)	OT0IRYG1	SUFU_HUMAN	Decreases Response To Substance	[8]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Decreases Response To Substance	[8]

Indication(s) of Raloxifene

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	Approved	[4]

Raloxifene Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[9]

Raloxifene Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Raloxifene Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[11]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[12]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Metabolism	[13]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Breast adenocarcinoma	DCBCZD3	MDA-MB-468	Investigative	[14]
Carcinoma	DCGGPPD	MCF7	Investigative	[14]
Colon adenocarcinoma	DCXMNUW	COLO 205	Investigative	[14]
Invasive ductal carcinoma	DC8B011	HS 578T	Investigative	[14]
Invasive ductal carcinoma	DCTITBA	BT-549	Investigative	[14]
Adenocarcinoma	DC8V720	DU-145	Investigative	[1]
Adenocarcinoma	DCBAFHM	A549	Investigative	[1]
Adenocarcinoma	DCSCZH7	NCIH23	Investigative	[1]
Adenocarcinoma	DCG5V75	SW-620	Investigative	[1]
Adenocarcinoma	DCKPC7T	HT29	Investigative	[1]
Adenocarcinoma	DCSX4OW	HCT-15	Investigative	[1]
Adult acute myeloid leukemia	DC960LC	HL-60(TB)	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCR7X9Q	MOLT-4	Investigative	[1]
Amelanotic melanoma	DC28RZ5	MDA-MB-435	Investigative	[1]
Amelanotic melanoma	DCV4KHG	M14	Investigative	[1]
Anaplastic large cell lymphoma	DCPKD6X	SR	Investigative	[1]
Astrocytoma	DCNP3A0	SNB-19	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DCJAZ2Y	CCRF-CEM	Investigative	[1]
Clear cell renal cell carcinoma	DC5ZJIR	786-0	Investigative	[1]
Clear cell renal cell carcinoma	DCQXTVS	TK-10	Investigative	[1]
Clear cell renal cell carcinoma	DCQ3FQ3	A498	Investigative	[1]
Cutaneous melanoma	DCSMVRE	SK-MEL-5	Investigative	[1]
Cutaneous melanoma	DCMQF10	SK-MEL-28	Investigative	[1]
Glioblastoma	DCAXJ0Z	SNB-75	Investigative	[1]
Glioma	DCPWZBB	SF-268	Investigative	[1]
Large cell lung carcinoma	DC2HHUV	NCI-H460	Investigative	[1]
Lung adenocarcinoma	DC9PTAM	HOP-62	Investigative	[1]
Malignant melanoma	DCG6YC0	LOX IMVI	Investigative	[1]
Malignant melanoma	DC5MM1J	UACC62	Investigative	[1]
Melanoma	DCDZG8W	SK-MEL-2	Investigative	[1]
Melanoma	DC7XWM3	UACC-257	Investigative	[1]
Minimally invasive lung adenocarcinoma	DC9GDB8	NCI-H322M	Investigative	[1]
Non-small cell lung carcinoma	DCYJ8OD	HOP-92	Investigative	[1]
Papillary renal cell carcinoma	DCN2BW1	ACHN	Investigative	[1]
Plasma cell myeloma	DCQ8S3Y	RPMI-8226	Investigative	[1]
Pleural epithelioid mesothelioma	DCEEDQU	NCI-H226	Investigative	[1]
Prostate carcinoma	DC2ZA3T	PC-3	Investigative	[1]
Renal cell carcinoma	DCZ667K	SN12C	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
• [3] A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [6] The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
• [7] Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.
• [8] Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul;20(7):732-40. doi: 10.1038/nm.3613. Epub 2014 Jun 29.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [10] Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
• [11] The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
• [12] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [13] Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
• [14] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.